Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.63 |
| ▸ | SLC40A1 | Q9NP59 | 6/20 | 0.59 |
| ▸ | GLO1 | Q04760 | 3/20 | 0.50 |
| ▸ | CKS1B | P61024 | 5/20 | 0.48 |
| ▸ | SKP2 | Q13309 | 5/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4474167 | 0.87 | SLC40A1 (0.61) | MEN1KMT2AAGTR1SLC40A1CKS1B | |
| SCHEMBL4472976 | 0.84 | SLC40A1 (0.67) | MEN1KMT2AAGTR1SLC40A1GLO1 | |
| SCHEMBL22076981 | 0.78 | MEN1 (1.00) | MEN1KMT2AAGTR1SLC40A1GLO1 | |
| SCHEMBL17506525 | 0.75 | CKS1B (0.71) | MEN1KMT2AAGTR1SLC40A1CKS1B | |
| SCHEMBL11973450 | 0.75 | SLC40A1 (1.00) | MEN1KMT2AAGTR1SLC40A1GLO1 | |
| SCHEMBL30854824 | 0.74 | ALDH1A1 (0.72) | MEN1KMT2AAGTR1SLC40A1TSHR | |
| SCHEMBL29255660 | 0.74 | ALDH1A1 (0.72) | MEN1KMT2AAGTR1SLC40A1TSHR | |
| SCHEMBL30925531 | 0.72 | SLC40A1 (0.64) | MEN1KMT2AAGTR1SLC40A1GLO1 | |
| SCHEMBL27214176 | 0.71 | SLC40A1 (0.67) | MEN1KMT2AAGTR1SLC40A1GLO1 | |
| SCHEMBL27214214 | 0.71 | MEN1 (0.60) | MEN1KMT2AAGTR1SLC40A1GLO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8470821-B2 | PDE4B inhibitors and uses therefor | PLEXXIKON INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-8470821-B2 | PDE4B inhibitors and uses therefor | PLEXXIKON INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20090286793-A1 | PDE4B INHIBITORS AND USES THEREFOR | PLEXXIKON, INC. | 2009-11-19 | — | — | US | disclosed |
| US-20090286793-A1 | PDE4B INHIBITORS AND USES THEREFOR | PLEXXIKON, INC. | 2009-11-19 | — | — | US | disclosed |
| US-7585859-B2 | PDE4B inhibitors and uses therefor | PLEXXIKON, INC. (US) | 2009-09-08 | — | — | US | disclosed |
| US-7585859-B2 | PDE4B inhibitors and uses therefor | PLEXXIKON, INC. (US) | 2009-09-08 | — | — | US | disclosed |
| US-7585859-B2 | PDE4B inhibitors and uses therefor | PLEXXIKON, INC. (US) | 2009-09-08 | — | — | US | disclosed |
| US-20060041006-A1 | PDE4B inhibitors and uses therefor | PLEXXIKON, INC. | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286793-A1 | PDE4B INHIBITORS AND USES THEREFOR | PDE4B, PDE7B, PDE4A | MEN1 2737/4885KMT2A 2234/4885AGTR1 2014/4885 |
| US-20060041006-A1 | PDE4B inhibitors and uses therefor | PDE4B, PDE7B, PDE4A | MEN1 2737/4885KMT2A 2234/4885AGTR1 2014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.